Depression is one of the leading mental illnesses worldwide and lowers the quality of life of
many. According to WHO, about 5% of the worldwide population suffers from depression …

Background Major depressive disorder [MDD] is expected to be the leading cause of overall
global burden of disease by the year 2030 [WHO]. Non-response to first line …

Aim To evaluate the efficacy and safety of an oral, once‐daily, 14‐day treatment course of
zuranolone in Japanese patients with major depressive disorder (MDD). Methods This …

Background Zuranolone is recognised as a promising antidepressant agent. Our study
aimed to investigate the efficacy and safety of zuranolone in treating major depressive …

This publication discusses two compounds belonging to the psychoactive substances group
which are studied in the context of depression treatment—psilocybin and esketamine. The …

Depression is a major global health issue that urgently requires innovative and precise
treatment options. In this context, saikosaponin has emerged as a promising candidate …

Ketamine is a promising alternative to traditional pharmacotherapies for major depressive
disorder, treatment-resistant depression, and other psychiatric conditions that heavily …

Major depressive disorder (MDD) and postpartum depression (PPD) are common and
burdensome conditions. This study aims to evaluate the efficacy and safety of zuranolone, a …

Psilocybin is a plant alkaloid that is derived from precursors of tryptamine and is present in
many different types of mushrooms. It has been utilized by indigenous peoples of Central …

Neuropsychiatric disorders are anticipated to be a leading health concern in the near future,
emphasizing an outstanding need for the development of new effective therapeutics to treat …